TY - JOUR
T1 - Infection of zebrafish larvae with human norovirus and evaluation of the in vivo efficacy of small-molecule inhibitors
AU - Van Dycke, Jana
AU - Cuvry, Arno
AU - Knickmann, Jan
AU - Ny, Annelii
AU - Rakers, Sebastian
AU - Taube, Stefan
AU - de Witte, Peter
AU - Neyts, Johan
AU - Rocha-Pereira, Joana
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2021/4
Y1 - 2021/4
N2 - We have recently established that human norovirus (HuNoV) replicates efficiently in zebrafish larvae after inoculation of a clinical sample into the yolk, providing a simple and robust in vivo system in which to study HuNoV. In this Protocol Extension, we present a detailed description of virus inoculation by microinjection, subsequent daily monitoring and harvesting of larvae, followed by viral RNA quantification. This protocol can be used to study viral replication of genogroup (G)I and GII HuNoVs in vivo within 3–4 d. Additionally, we describe how to evaluate the in vivo antiviral effect and toxicity of small molecules using HuNoV-infected zebrafish larvae, in multi-well plates and without the need for specific formulations. This constitutes a great advantage for drug discovery efforts, as no specific antivirals or vaccines currently exist to treat or prevent norovirus gastroenteritis.
AB - We have recently established that human norovirus (HuNoV) replicates efficiently in zebrafish larvae after inoculation of a clinical sample into the yolk, providing a simple and robust in vivo system in which to study HuNoV. In this Protocol Extension, we present a detailed description of virus inoculation by microinjection, subsequent daily monitoring and harvesting of larvae, followed by viral RNA quantification. This protocol can be used to study viral replication of genogroup (G)I and GII HuNoVs in vivo within 3–4 d. Additionally, we describe how to evaluate the in vivo antiviral effect and toxicity of small molecules using HuNoV-infected zebrafish larvae, in multi-well plates and without the need for specific formulations. This constitutes a great advantage for drug discovery efforts, as no specific antivirals or vaccines currently exist to treat or prevent norovirus gastroenteritis.
UR - http://www.scopus.com/inward/record.url?scp=85104272587&partnerID=8YFLogxK
U2 - 10.1038/s41596-021-00499-0
DO - 10.1038/s41596-021-00499-0
M3 - Scientific review articles
C2 - 33837302
AN - SCOPUS:85104272587
SN - 1754-2189
VL - 16
SP - 1830
EP - 1849
JO - Nature Protocols
JF - Nature Protocols
IS - 4
ER -